ArticleISRN oncology2012
Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells.
Article in ISRN oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 64 citations in OpenAlex.
- Chimeric Antigen Receptor (CAR) T-Cell Therapy for Patients with Lung Cancer: Current Perspectives.OncoTargets and therapy · 2023Review
- Article
- Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions.Frontiers in bioengineering and biotechnology · 2022Review
- Engineering of chimeric natural killer cell receptors to develop precision adoptive immunotherapies for cancer.Clinical and experimental immunology · 2020Review
- Genetically Modified T-Cell Therapy for Osteosarcoma: Into the Roaring 2020s.Advances in experimental medicine and biology · 2020Review
- Oncolytic Virus Combination Therapy: Killing One Bird with Two Stones.Molecular therapy : the journal of the American Society of Gene Therapy · 2018Review
- Quarter Century of Anti-HIV CAR T Cells.Current HIV/AIDS reports · 2018Review
- T-cell Immunotherapies and the Role of Nonclinical Assessment: The Balance between Efficacy and Pathology.Toxicologic pathology · 2018Review
- Clinical Grade Regulatory CD4Frontiers in immunology · 2018Review
- Article
- Folate receptor 1 (FOLR1) targeted chimeric antigen receptor (CAR) T cells for the treatment of gastric cancer.PloS one · 2018Article
- Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies.Journal of immunology research · 2018Review
- Prospects for combined use of oncolytic viruses and CAR T-cells.Journal for immunotherapy of cancer · 2017Review
- Human CD3+ T-Cells with the Anti-ERBB2 Chimeric Antigen Receptor Exhibit Efficient Targeting and Induce Apoptosis in ERBB2 Overexpressing Breast Cancer Cells.International journal of molecular sciences · 2017Article
- Combining Cell and Gene Therapy in an Effort to Eradicate HIV.AIDS patient care and STDs · 2016Article
- Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist.The oncologist · 2016Review
- Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells.Oncoimmunology · 2016Article
- Expression of inhibitory receptors on intratumoral T cells modulates the activity of a T cell-bispecific antibody targeting folate receptor.Oncoimmunology · 2016Article
- CAR T-cell immunotherapy: The path from the by-road to the freeway?Molecular oncology · 2015Review
- Cell mediators of autoimmune hepatitis and their therapeutic implications.Digestive diseases and sciences · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chimeric antigen receptor- (CAR-) based immunotherapy has been under development for almost 25 years, over which period it has progressed from a new but cumbersome technology to an emerging therapeutic modality for malignant disease. The approach involves the genetic engineering of fusion receptors (CARs) that couple the HLA-independent binding of cell surface target molecules to the delivery of a tailored activating signal to host immune cells. Engineered CARs are delivered most commonly to peripheral blood T cells using a range of vector systems, most commonly integrating viral vectors. Preclinical refinement of this approach has proceeded over several years to the point that clinical testing is now being undertaken at several centres, using increasingly sophisticated and therapeutically successful genetic payloads. This paper considers several aspects of the pre-clinical and clinical development of CAR-based immunotherapy and how this technology is acquiring an increasing niche in the treatment of both solid and haematological malignancies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.